Company: BDRX
Filing Date: 2025-05-23
Form Type: 6-K
Source: 0001214659-25-008302
Chunk: 0

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-23
Form: 6-K
Chunk 0
---
<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of May 2025

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:

Form 20-F x Form
40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

<div align='center'>EXPLANATORY NOTE</div>

On May 23, 2025, Biodexa Pharmaceuticals
PLC (the “Company”) posted its Annual Report for the year ended December 31, 2024 (the “Annual Report”) and distributed
a Notice of Annual General Meeting (the “AGM Notice”) to its shareholders. The Company has also disseminated to its (i) holders
of ordinary shares, nominal value £0.00005 per share, a proxy form for the Annual General Meeting (the “Ordinary Shares AGM
Proxy Form”) and (ii) holders of American Depositary Shares, a proxy form for the Annual General Meeting (the “ADS AGM Proxy
Form”). The Annual General Meeting is scheduled to take place on June 26, 2025 at 1:00 p.m. (London time) at the Company’s
registered office at 1 Caspian Point, Caspian Way, Cardiff, Wales, CF10 4DQ.

A copy of the Annual Report,
AGM Notice, Ordinary Shares AGM Proxy Form and ADS AGM Proxy Form are attached hereto as Exhibits 99.1, 99.2, 99.3, and 99.4 respectively.

The